IEX •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization65.49 mln
Float26.53 mln
Earnings Date11/18/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
11.70
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-61.79
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Tenax Therapeutics is a US-based pharmaceutical company focused on developing new treatments for serious heart and lung conditions. Its lead programs include levosimendan, which has completed Phase II trials for pulmonary hypertension in heart failure patients, and imatinib, a targeted therapy originally used in blood cancer treatment. Founded in 1967 and headquartered in Chapel Hill, North Carolina, the company was previously known as Oxygen Biotherapeutics before adopting its current name in 2014.
